[ATLANTIC trial and feasibility of early administration of ticagrelor in myocardial infarction]

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• ST-segment elevation myocardial infarction (STEMI) requires rapid reperfusion therapy.
• Ticagrelor is a P2Y12 inhibitor used in acute coronary syndromes.
• Optimal timing for ticagrelor initiation in STEMI remains under investigation.

Purpose of the Study:

• To compare the safety and efficacy of prehospital versus in-hospital initiation of ticagrelor in STEMI patients undergoing percutaneous coronary intervention (PCI).

Main Methods:

• The ATLANTIC trial randomized STEMI patients to receive ticagrelor prehospital (in ambulance) or in-hospital (catheterization laboratory).
• Outcomes assessed included coronary reperfusion before PCI and stent thrombosis after PCI.

Main Results:

• Prehospital ticagrelor initiation was safe and did not significantly improve pre-PCI coronary reperfusion.
• Early administration of ticagrelor significantly reduced the incidence of stent thrombosis post-PCI.

Conclusions:

• Prehospital ticagrelor initiation in STEMI patients is safe but does not enhance early reperfusion.
• Earlier ticagrelor administration is associated with a reduced risk of stent thrombosis following PCI.